Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Mild to moderate hypertension (adjunctive therapy),Psychotic disorders (off-label),Tardive dyskinesia (off-label),Huntington disease (off-label)
Hypertension
Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Terminal elimination half-life 45–168 hours (mean 100 h), reflecting prolonged adrenergic depletion; clinical effects persist beyond serum presence.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Reserpine is extensively metabolized in the liver via hydrolysis and glucuronidation; specific CYP enzymes are not well characterized.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Primarily renal (approx. 60% unchanged and metabolites), biliary/fecal (approx. 40%), enterohepatic circulation negligible.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
~96% bound to plasma proteins (albumin and lipoproteins).
Approximately 70-80% bound to plasma proteins, primarily albumin.
Vd 9.4 L/kg, indicating extensive tissue binding (particularly adrenergic neurons, brain, adipose).
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: 30–40% due to extensive first-pass metabolism; IM/IV: 100%.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
No specific dose adjustment; use cautiously in severe renal impairment (Cr Cl <30 m L/min) due to risk of hypotension and CNS effects.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to risk of hepatic encephalopathy.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Hypertension: 0.02 mg/kg/day orally divided every 6–12 hours; maximum 0.25 mg/day. Psychosis: not recommended.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Initiate at 0.05 mg orally once daily; increase slowly due to increased sensitivity and risk of hypotension, sedation, and depression.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None
None.
May cause severe depression with risk of suicide (discontinue if depression occurs),Use with caution in patients with history of peptic ulcer disease (increases gastric acid secretion),Use with caution in patients with renal impairment (may reduce renal blood flow),Avoid concomitant use with MAOIs (risk of hypertensive crisis),Electroshock therapy: discontinue reserpine 7-14 days prior,May cause biliary colic in patients with gallstones,May exacerbate arrhythmias in patients with cardiac disease
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Hypersensitivity to reserpine or any component,History of depression (especially suicidal),Active peptic ulcer disease,Ulcerative colitis,Electroconvulsive therapy (within 7-14 days),Concurrent MAO inhibitor therapy (or within 2 weeks of discontinuation),Pheochromocytoma
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products, soy sauce, yeast extracts) as reserpine can potentiate pressor responses, leading to hypertensive crisis. Alcohol may increase sedative effects. Grapefruit juice may alter drug metabolism; limit intake.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
Reserpine (Serpasil) crosses the placenta. First trimester: no clear evidence of major malformations but risk of fetal bradycardia and hypothermia. Second and third trimesters: risk of neonatal bradycardia, hypotonia, lethargy, and respiratory depression. Use only if benefits outweigh risks.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Reserpine is excreted into breast milk. M/P ratio not established. Risk of infant bradycardia, GI upset, and nasal congestion. Not recommended during breastfeeding.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No specific dose adjustment guidelines. Consider lower starting doses due to increased sensitivity. Monitor maternal blood pressure closely to avoid hypotension.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Serpasil (reserpine) is an antihypertensive and antipsychotic that depletes catecholamines from peripheral sympathetic nerve endings and CNS. Onset is slow (3-6 days) and effects persist for weeks after discontinuation. Monitor for depression, especially in patients with history. Avoid in patients requiring MAOIs due to hypertensive crisis risk. Use with caution in peptic ulcer disease due to increased gastric acid secretion. Bradycardia and nasal congestion are common side effects.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take exactly as prescribed; do not stop suddenly as blood pressure may rise rapidly.,Report any symptoms of depression, mood changes, or suicidal thoughts immediately.,Avoid alcohol and over-the-counter cold or allergy medications containing decongestants.,May cause drowsiness or dizziness; avoid driving until you know how the drug affects you.,Contact your healthcare provider if you experience slow heartbeat, fainting, or severe stomach pain.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL vs ALDOCLOR-150, answered by our medical review team.
SERPASIL is a Antihypertensive that works by Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL is: Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL is classified as Category C. Reserpine (Serpasil) crosses the placenta. First trimester: no clear evidence of major malformations but risk of fetal bradycardia and hypothermia. Second and third trimesters: ris. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.